Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Kirsten Reuter-Jessen"'
Autor:
Margaretha A. Skowron, Mara Kotthoff, Felix Bremmer, Katja Ruhnke, Fatma Parmaksiz, Annika Richter, Stefan Küffer, Kirsten Reuter-Jessen, Stella Pauls, Anja Stefanski, Philipp Ströbel, Kai Stühler, Daniel Nettersheim
Publikováno v:
Molecular Medicine, Vol 29, Iss 1, Pp 1-15 (2023)
Abstract Background Being the standard-of-care for four decades, cisplatin-based chemotherapy is highly efficient in treating germ cell tumors (GCT). However, often refractory patients present with a remaining (resistant) yolk-sac tumor (YST(-R)) com
Externí odkaz:
https://doaj.org/article/caf7ef9e806d4a1ba23d65a22dace983
Autor:
Soeren M. Buchholz, Nelia Nause, Ute König, Johanna Reinecke, Benjamin Steuber, Christoph Ammer-Herrmenau, Kirsten Reuter-Jessen, Hanibal Bohnenberger, Lorenz Biggemann, Friederike Braulke, Albrecht Neesse, Volker Ellenrieder, Philipp Ströbel, Marius Adler, Alexander König
Publikováno v:
Journal of Personalized Medicine, Vol 13, Iss 12, p 1701 (2023)
Receptor tyrosine kinase erythroblastic oncogene B2 (ERBB2), also known as human epidermal growth factor receptor 2 (HER2), represents an oncogenic driver and has been effectively targeted in breast and gastric cancer. Recently, next-generation seque
Externí odkaz:
https://doaj.org/article/9530af06ceb247a88963f19e48490b76
Autor:
Tobias Raphael Overbeck, Annika Reiffert, Katja Schmitz, Achim Rittmeyer, Wolfgang Körber, Sara Hugo, Juliane Schnalke, Laura Lukat, Tabea Hugo, Marc Hinterthaner, Kirsten Reuter-Jessen, Hans-Ulrich Schildhaus
Publikováno v:
Cancers, Vol 15, Iss 11, p 2966 (2023)
(1) Background: The main objectives of our study are (i) to determine the prevalence of NTRK (neurotrophic tyrosine kinase) fusions in a routine diagnostic setting in NSCLC (non-small cell lung cancer) and (ii) to investigate the feasibility of scree
Externí odkaz:
https://doaj.org/article/49345250d629498fa0182adab8e33929
Autor:
Omar Elakad, Anna‐Maria Lois, Katja Schmitz, Sha Yao, Sara Hugo, Laura Lukat, Marc Hinterthaner, Bernhard C. Danner, Alexander vonHammerstein‐Equord, Kirsten Reuter‐Jessen, Hans‐Ulrich Schildhaus, Philipp Ströbel, Hanibal Bohnenberger
Publikováno v:
Cancer Medicine, Vol 9, Iss 10, Pp 3574-3583 (2020)
Abstract Background Targeting fibroblast growth factor receptor 1 (FGFR1) is a potential treatment for squamous cell lung cancer (SQCLC). So far, treatment decision in clinical studies is based on gene amplification. However, only a minority of patie
Externí odkaz:
https://doaj.org/article/b11316f0c4c94414ad45bc3cdf35f622
Autor:
Peter Jo, Markus Bernhardt, Manuel Nietert, Alexander König, Azadeh Azizian, Markus A Schirmer, Marian Grade, Julia Kitz, Kirsten Reuter-Jessen, Michael Ghadimi, Philipp Ströbel, Hans-Ulrich Schildhaus, Jochen Gaedcke
Publikováno v:
PLoS ONE, Vol 15, Iss 10, p e0239806 (2020)
IntroductionOncogenic mutation within the KRAS gene represents a negative predictor for treatment response to anti-epidermal growth factor receptor (EGFR) in patients with colorectal cancer. Recently, we have shown no relevant heterogeneity for KRAS
Externí odkaz:
https://doaj.org/article/8454fd50dbbb446fb84ef6e648d802fc
Autor:
Hanibal Bohnenberger, Lars Kaderali, Philipp Ströbel, Diego Yepes, Uwe Plessmann, Neekesh V Dharia, Sha Yao, Carina Heydt, Sabine Merkelbach‐Bruse, Alexander Emmert, Jonatan Hoffmann, Julius Bodemeyer, Kirsten Reuter‐Jessen, Anna‐Maria Lois, Leif Hendrik Dröge, Philipp Baumeister, Christoph Walz, Lorenz Biggemann, Roland Walter, Björn Häupl, Federico Comoglio, Kuan‐Ting Pan, Sebastian Scheich, Christof Lenz, Stefan Küffer, Felix Bremmer, Julia Kitz, Maren Sitte, Tim Beißbarth, Marc Hinterthaner, Martin Sebastian, Joachim Lotz, Hans‐Ulrich Schildhaus, Hendrik Wolff, Bernhard C Danner, Christian Brandts, Reinhard Büttner, Martin Canis, Kimberly Stegmaier, Hubert Serve, Henning Urlaub, Thomas Oellerich
Publikováno v:
EMBO Molecular Medicine, Vol 10, Iss 9, Pp n/a-n/a (2018)
Abstract Patients with head‐and‐neck cancer can develop both lung metastasis and primary lung cancer during the course of their disease. Despite the clinical importance of discrimination, reliable diagnostic biomarkers are still lacking. Here, we
Externí odkaz:
https://doaj.org/article/9e1b98ca39654a949c2bd368ebedd85e
Autor:
Christian, Kromer, Lyubomira D, Vlahova, Katharina, Julius, Viktor, Schnabel, Michael P, Schön, Kirsten, Reuter-Jessen, Ali, Seif Amir Hosseini, Lutz, Kretschmer
Publikováno v:
Melanoma Research. 32:124-127
Autor:
Kirsten Reuter-Jessen, Philipp Ströbel
Publikováno v:
Der Onkologe. 28:95-99
Autor:
Kirsten Reuter-Jessen, Tessa Rosenthal, Laura Lukat, Annalen Bleckmann, Sara Hugo, Katja Schmitz, Achim Rittmeyer, Juliane Schnalke, Hans-Ulrich Schildhaus, Marc Hinterthaner, Wolfgang Körber, Dana Alina Cron, Joachim Moecks, Tabea Hugo, Tobias Overbeck
Publikováno v:
Translational Lung Cancer Research. 9:603-616
Ca Schildhaus Background: MET amplifications occur in human tumors, including non-small cell lung cancer (NSCLC). MET inhibitors have demonstrated some clinical activity in MET amplified NSCLC, presumably with a gene dose effect. However, the definit
Autor:
Martin Schuler, Hans-Ulrich Schildhaus, Sebastian Bauer, Dietrich Kämpfe, Farhad Farzaliyev, Rainer Hamacher, Kirsten Reuter-Jessen, Christoph Pöttgen, Lars Erik Podleska, Hans-Ulrich Steinau
Publikováno v:
JCO Precision Oncology. :1-7